Brought to you by 
Merix Bioscience completes $39.5mm second round
24 Sep 2001
Executive Summary
Merix Bioscience (cancer vaccines) has raised $39.5mm with a second round financing. Lead investors Sofinov and Techno Venture Management were joined by new investors ABN Amro Ventures BV, GeneChem Therapeutics Venture Fund LP, Oakwood Medical Investors, Pacific Horizon Partners, Sanders Morris Harris, SHV Ventures, and TFG Venture Capital.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merix Bioscience completes $39.5mm second round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice